Acesso livre
Acesso livre

Farmácia/Notícias da Indústria

M-A de estudos randomizados | Ondansentrona vs. metoclopramida no tratamento da hiperêmese gravídica.

5 Jul, 2022 | 11:27h

Ondansetron versus metoclopramide for managing hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trials – Turkish Journal Of Obstetrics And Gynecology

Revisão | Redução e aumento dos níveis de urato sérico: efeitos off-label de medicações comumente usadas.

5 Jul, 2022 | 11:26h

Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications – Mayo Clinic Proceedings

FDA alerta sobre possível risco aumentado de morte e de sérios efeitos adversos com uso de duvelisibe.

5 Jul, 2022 | 11:21h

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib – The ASCO Post

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo randomizado | Uma dose única e imediata de tenecteplase é não inferior à alteplase para tratar pacientes com AVC isquêmico agudo.

4 Jul, 2022 | 12:21h

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial – The Lancet (link para o resumo – $ para o texto completo)

Comunicado de imprensa: UCalgary researchers with the Calgary Stroke Program make another breakthrough in the treatment of stroke

Estudo de coorte | Efetividade das vacinas Pfizer, Moderna e AstraZeneca contra desfechos graves de Covid-19 em um cenário de vacinação em massa de abrangência nacional.

4 Jul, 2022 | 12:16h

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study – BMJ Medicine

 

Comentário no Twitter

 

Estudo randomizado | Oxaliplatina (3 meses vs. 6 meses) com 6 meses de fluoropirimidina como terapia adjuvante em pacientes com câncer de cólon estágios II/III.

4 Jul, 2022 | 11:54h

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 – Journal of Clinical Oncology

Estudo relacionado: Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial – Journal of Clinical Oncology

M-A | Analgesia com opioide vs. sem opioide após alta cirúrgica.

22 Jun, 2022 | 21:43h

Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials – The Lancet (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Taking opioids at home after surgery: More harms than benefits – McGill University Health Center

Onconefrologia: atualização da nefrotoxicidade relacionada à medicação anticâncer.

22 Jun, 2022 | 21:20h

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron

Conteúdos relacionados:

Acute Kidney Injury in Critically Ill Patients with Cancer – Clinical Journal of the American Society of Nephrology

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

Comentário da autora no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.